Patents by Inventor Gunther Hartmann

Gunther Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11014956
    Abstract: The present disclosure provides, among other things, compounds comprising cyclic dinucleotides containing a 2',5' linkage useful in the design of research tools, as research tools, and as therapeutic modalities such as enzyme modulators.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 25, 2021
    Assignees: Memorial Sloan Kettering Cancer Center; The Rockefeller, University; Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10598207
    Abstract: A high-strength screw (2) includes a threaded portion (7) having a thread (8). The screw (2) includes an inner core (16) as seen in cross-section of the screw (2), the core (16) having a first hardness. The screw (2) includes an outer surface layer (17) as seen in cross-section of the screw (2). The screw (2) includes an unhardening layer (18) forming the outer surface layer (17) in the threaded portion (7), the unhardening layer (18) having a second hardness being reduced compared to the first hardness of the core (16).
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 24, 2020
    Assignee: KAMAX HOLDING GMBH & CO. KG
    Inventors: Gunther Hartmann, Horst Dieterle
  • Publication number: 20190330257
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 31, 2019
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, JR., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10385091
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: August 20, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10238682
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 10196638
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 5, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Publication number: 20190030072
    Abstract: The present invention pertains to extracellular vesicles (exosomes) that are produced by culturing tumor cells in the presence of various ligands or activators of innate immunity receptors and subsequently isolating and purifying the vesicles in the culture supernatant. The invention provides also pharmaceutical compositions comprising the inventive exosomes. The exosomes of the invention are provided as medicaments for example in the treatment of cancer diseases.
    Type: Application
    Filed: July 30, 2018
    Publication date: January 31, 2019
    Inventors: Christoph COCH, Juliane DASSLER-PLENKER, Gunther HARTMANN
  • Patent number: 10176292
    Abstract: The present invention provides STING crystals. The present invention also provides STING modulators that interact with sites present in and/or defined by such crystals. The present invention also provides methods of making and using such crystals and modulators. Other aspects and/or features of the present invention will be apparent to those skilled in the art, reading the present specification.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: January 8, 2019
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Roger Jones, Gunther Hartmann, Winfried Barchet, Thomas Zillinger, Weiyi Wang, Pu Gao, Liang Deng, Manuel Ascano, Jr.
  • Patent number: 10174326
    Abstract: The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: January 8, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Winfried Barchet, Vera Wimmenauer
  • Patent number: 10131686
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 20, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10036021
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: July 31, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Publication number: 20180156257
    Abstract: A high-strength screw (1) includes a head (2) having a tool engagement external contour (7) and a tool engagement internal contour (8). For example, the tool engagement external contour (7) is an external hexagonal and the tool engagement internal contour (8) is an internal hexagonal. A plurality of additional pocket-shaped impressions (13) are arranged in the tool engagement internal contour (8) between corners (12).
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Reiner Rühl, Thorsten Schmitt, Gunther Hartmann, Manuel Kellner, Klaus-Günter Vennemann
  • Publication number: 20180127454
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 10, 2018
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Publication number: 20180118777
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: September 28, 2017
    Publication date: May 3, 2018
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Publication number: 20180031023
    Abstract: A high-strength screw (2) includes a threaded portion (7) having a thread (8). The screw (2) includes an inner core (16) as seen in cross-section of the screw (2), the core (16) having a first hardness. The screw (2) includes an outer surface layer (17) as seen in cross-section of the screw (2). The screw (2) includes an unhardening layer (18) forming the outer surface layer (17) in the threaded portion (7), the unhardening layer (18) having a second hardness being reduced compared to the first hardness of the core (16).
    Type: Application
    Filed: July 26, 2017
    Publication date: February 1, 2018
    Inventors: Gunther Hartmann, Horst Dieterle
  • Patent number: 9840533
    Abstract: The present disclosure provides, among other things, novel cyclic-GMP-AMP (cGAMP) analogs, mimics, mimetics and variants, and compositions and kits thereof; methods of using the compounds as described herein for treating cancer, and immune disease, disorders, or conditions; methods of using the compounds as described herein for modulating cGAS and STING; and methods of designing or characterizing a cGAS modulator.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 12, 2017
    Assignees: Memorial Sloan Kettering Cancer Center, Rutgers, The State University of New Jersey, The Rockefeller University, University of Bonn
    Inventors: Dinshaw Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 9738680
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 22, 2017
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Publication number: 20160333347
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Application
    Filed: May 10, 2016
    Publication date: November 17, 2016
    Inventors: Gunther Hartmann, Martin Schlee
  • Publication number: 20160333352
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Application
    Filed: May 10, 2016
    Publication date: November 17, 2016
    Inventors: Gunther Hartmann, Martin Schlee
  • Patent number: 9409941
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 9, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee